Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis

Background: This study aimed to evaluate the safety and efficacy of first-line nivolumab plus chemotherapy for real-world patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (AGC). Materials and methods: This single-institutional retrospective study enrolle...

Full description

Bibliographic Details

Published in:	ESMO Gastrointestinal Oncology
Main Authors:	K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Subjects:	gastric or gastroesophageal junction cancer nivolumab PD-L1 early tumor shrinkage depth of response
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949819824000335